Summary of bi-shRNA/GM-CSF augmented autologous tumor cell immunotherapy (FANG™) in advanced cancer of the liver.
about
Novel Furin Inhibitors with Potent Anti-infectious ActivityDysregulation of TGFβ1 Activity in Cancer and Its Influence on the Quality of Anti-Tumor ImmunityMolecular mechanisms for enhanced DNA vaccine immunogenicity.Proprotein convertase inhibition: Paralyzing the cell's master switches.Phase 1 Trial of Bi-shRNA STMN1 BIV in Refractory Cancer.Preclinical Justification of pbi-shRNA EWS/FLI1 Lipoplex (LPX) Treatment for Ewing's Sarcoma.T-cell-expressed proprotein convertase FURIN inhibits DMBA/TPA-induced skin cancer development.The proprotein convertase furin is required to maintain viability of alveolar rhabdomyosarcoma cells.Immune Therapy for Sarcomas.From the RNA world to the clinic.Overexpression of apolipoprotein A-I fused to an anti-transforming growth factor beta peptide modulates the tumorigenicity and immunogenicity of mouse colon cancer cells.Promising new strategies for hepatocellular carcinoma.The proprotein convertase furin in tumour progression.Cellular and molecular targets for the immunotherapy of hepatocellular carcinoma.Tumor vaccines and cellular immunotherapies.Using Genome Sequence to Enable the Design of Medicines and Chemical Probes.Targeting proprotein convertases in furin-rich lung cancer cells results in decreased in vitro and in vivo growth.Immunotherapy for Hepatocellular Carcinoma: Current Advances and Future Expectations.
P2860
Q27700845-52B65F18-AD92-47F7-8C91-2DF4C70849FEQ28075996-7853C5F7-8A97-4F56-846C-322A834317F9Q30366743-340AD884-69F9-47FD-8055-9B174EFB986FQ36358957-24C3FC86-08B1-4D6E-B04A-F73C1C8EFED6Q36756699-100FD891-EF91-4F88-BD01-CFECF6844567Q37256170-FCD15944-FBB4-4AD6-AE54-64916178F13EQ37558166-4F0E9749-1E22-45CB-8E89-3807B5DA0ACCQ37718282-1AAC196D-A622-4A9D-9C95-F5C88050774CQ38742533-52BC62D6-1ED1-472A-AA3B-B3053BE2B28CQ38851919-DE18855C-3B83-4990-91D0-550A47875E28Q38896948-0C05CE99-4F03-43AC-A47E-8CFF04D1E31DQ38936589-6056AEEE-5CB4-4E01-BD17-0C1A98D6A088Q39215671-8FD717EB-F4D6-4A21-8FCE-12E7E26D6427Q39358916-BAA1F06F-4920-4B06-A8DD-B4C7763FB881Q42370386-9EF07522-639D-4E3A-BF49-8F378A16174EQ48263612-EB997ED2-6B36-49BC-8520-2B120FEEEE6AQ51538787-EAF25D72-5928-4F6B-99A5-FF0179E874CAQ54963955-0FAF198C-1824-4B46-B5FA-075174CB8038
P2860
Summary of bi-shRNA/GM-CSF augmented autologous tumor cell immunotherapy (FANG™) in advanced cancer of the liver.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Summary of bi-shRNA/GM-CSF aug ...... advanced cancer of the liver.
@en
Summary of bi-shRNA/GM-CSF augmented autologous tumor cell immunotherapy
@nl
type
label
Summary of bi-shRNA/GM-CSF aug ...... advanced cancer of the liver.
@en
Summary of bi-shRNA/GM-CSF augmented autologous tumor cell immunotherapy
@nl
prefLabel
Summary of bi-shRNA/GM-CSF aug ...... advanced cancer of the liver.
@en
Summary of bi-shRNA/GM-CSF augmented autologous tumor cell immunotherapy
@nl
P2093
P356
P1433
P1476
Summary of bi-shRNA/GM-CSF aug ...... advanced cancer of the liver.
@en
P2093
Alyssa Roth
Beena O Pappen
Cynthia Bedell
Derek Nemunaitis
Douglas Orr
Gladice Wallraven
Jeffrey Lamont
John Nemunaitis
Joseph Kuhn
Minal Barve
P356
10.1159/000360993
P577
2014-06-25T00:00:00Z